This company listing is no longer active
Biotest (BIO3) Stock Overview
Develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
BIO3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €29.80 |
| 52 Week High | €31.00 |
| 52 Week Low | €24.70 |
| Beta | 0.094 |
| 1 Month Change | -0.67% |
| 3 Month Change | 3.47% |
| 1 Year Change | 13.31% |
| 3 Year Change | -14.86% |
| 5 Year Change | 46.08% |
| Change since IPO | 27.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIO3 | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | -0.7% | -5.3% | -1.8% |
| 1Y | 13.3% | 13.2% | 19.6% |
Return vs Industry: BIO3 exceeded the Austrian Biotechs industry which returned 6.3% over the past year.
Return vs Market: BIO3 underperformed the Austrian Market which returned 15.9% over the past year.
Price Volatility
| BIO3 volatility | |
|---|---|
| BIO3 Average Weekly Movement | 2.1% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in AT Market | 7.1% |
| 10% least volatile stocks in AT Market | 2.6% |
Stable Share Price: BIO3 has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: BIO3's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,495 | Peter Janssen | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine.
Biotest Aktiengesellschaft Fundamentals Summary
| BIO3 fundamental statistics | |
|---|---|
| Market cap | €1.40b |
| Earnings (TTM) | -€24.50m |
| Revenue (TTM) | €635.20m |
Is BIO3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO3 income statement (TTM) | |
|---|---|
| Revenue | €635.20m |
| Cost of Revenue | €487.90m |
| Gross Profit | €147.30m |
| Other Expenses | €171.80m |
| Earnings | -€24.50m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 04, 2025
| Earnings per share (EPS) | -0.62 |
| Gross Margin | 23.19% |
| Net Profit Margin | -3.86% |
| Debt/Equity Ratio | 131.2% |
How did BIO3 perform over the long term?
See historical performance and comparisonDividends
Does BIO3 pay a reliable dividends?
See BIO3 dividend history and benchmarks| Biotest dividend dates | |
|---|---|
| Ex Dividend Date | Jul 03 2025 |
| Dividend Pay Date | Jul 07 2025 |
| Days until Ex dividend | 265 days |
| Days until Dividend pay date | 261 days |
Does BIO3 pay a reliable dividends?
See BIO3 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/11 09:35 |
| End of Day Share Price | 2025/06/06 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biotest Aktiengesellschaft is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Torben Teichler | Hauck Aufhäuser Investment Banking |
| Jan Keppeler | HSBC |
| Klaus Schlote | Solventis Wertpapierhandelsbank GmbH |